Loading...
Please wait, while we are loading the content...
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant $Ph^{1}$ (+) acute myeloid leukemia
| Content Provider | Scilit |
|---|---|
| Author | Viniou, Nora-Athina Vassilakopoulos, Theodoros P. Giakoumi, Xanthi Mantzouranis, Marina Pangalis, Gerassimos A. |
| Copyright Year | 2003 |
| Description | Journal: European Journal of Haematology Imatinib mesylate is a potent, selective inhibitor of the tyrosine kinase activity of bcr-abl,which is now established as the state-of-the-art treatment for chronic, accelerated or even blastic phase of Philadelphia-positive [Ph(1)(+)] chronic myelogenous leukemia. It is also active in Ph(1)(+) acute lymphoblastic leukemia, but its role in Ph(1)(+) acute myeloid leukemia (AML) is less well investigated. We report here a patient with chemoresistant Ph(1)(+) AML, who responded promptly to one cycle of Ida-FLAG second-line chemotherapy by achieving complete morphologic, immunophenotypic, and cytogenetic remission but not a molecular one. The addition of imatinib mesylate led to a molecular remission, which is sustained for 10 months so far. |
| Ending Page | 60 |
| Starting Page | 58 |
| ISSN | 2573508X |
| e-ISSN | 16000609 |
| DOI | 10.1046/j.0902-4441.2004.00175.x |
| Journal | European Journal of Haematology |
| Issue Number | 1 |
| Volume Number | 72 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2003-12-22 |
| Access Restriction | Open |
| Subject Keyword | Journal: European Journal of Haematology Imatinib Mesylate Molecular Remission Ida Flag |
| Content Type | Text |
| Resource Type | Article |
